Trial Profile
Phase III study of F901318 for invasive aspergillosis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Olorofim (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Registrational; Therapeutic Use
- Sponsors F2G
- 11 Jul 2016 According to an F2G media release, the company plans to initiate this trial in 1H 2017.
- 24 Jun 2016 New trial record
- 20 Jun 2016 According to F2G media release, thae company plans to initiate this trial in the second half of 2016.